Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2 CAD | 0.00% | -4.76% | -36.51% |
Valuation
Fiscal Period: May | 2021 | 2022 | 2023 |
---|---|---|---|
Capitalization 1 | 19.53 | 13.13 | 9.699 |
Enterprise Value (EV) 1 | 13.65 | 1.007 | 3.445 |
P/E ratio | 7 x | -3 x | -1.51 x |
Yield | - | - | - |
Capitalization / Revenue | - | - | - |
EV / Revenue | - | - | - |
EV / EBITDA | -5,616,845 x | -254,234 x | -870,412 x |
EV / FCF | -13,533,150 x | -523,177 x | -1,787,976 x |
FCF Yield | -0% | -0% | -0% |
Price to Book | 3.4 x | 1.12 x | 1.79 x |
Nbr of stocks (in thousands) | 69,735 | 87,522 | 88,169 |
Reference price 2 | 0.2800 | 0.1500 | 0.1100 |
Announcement Date | 07/09/21 | 28/09/22 | 28/09/23 |
Income Statement Evolution (Annual data)
Fiscal Period: May | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net sales | - | - | - | - |
EBITDA | - | -2.43 | -3.96 | -3.958 |
EBIT 1 | -0.1429 | -2.43 | -3.962 | -3.96 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | -0.1429 | 2.889 | -4.236 | -6.416 |
Net income 1 | -0.1429 | 2.664 | -4.011 | -6.416 |
Net margin | - | - | - | - |
EPS | - | 0.0400 | -0.0500 | -0.0728 |
Free Cash Flow | - | -1.008 | -1.924 | -1.927 |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 22/07/20 | 07/09/21 | 28/09/22 | 28/09/23 |
Income Statement Evolution (Quarterly data)
Fiscal Period: May | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA 1 | -1.037 | -1.087 | -1.463 | -1.221 | -0.8303 |
EBIT 1 | -1.037 | -1.087 | -1.464 | -1.222 | -0.8307 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - |
Net income | - | - | - | - | - |
Net margin | - | - | - | - | - |
EPS | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 27/01/22 | 25/04/22 | 28/09/22 | 26/10/22 | 26/01/23 |
Balance Sheet Analysis
Fiscal Period: May | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | 0.39 | 5.88 | 12.1 | 6.25 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | -1.01 | -1.92 | -1.93 |
ROE (net income / shareholders' equity) | - | 89.4% | -46.1% | -74.4% |
ROA (Net income/ Total Assets) | - | -48% | -27.3% | -26.8% |
Assets 1 | - | -5.556 | 14.67 | 23.95 |
Book Value Per Share 2 | 0.0100 | 0.0800 | 0.1300 | 0.0600 |
Cash Flow per Share 2 | 0.0100 | 0.0400 | 0.1000 | 0.0700 |
Capex | - | 0 | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 22/07/20 | 07/09/21 | 28/09/22 | 28/09/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-36.51% | 12.93M | |
+55.95% | 811B | |
+43.62% | 640B | |
-6.98% | 353B | |
+19.08% | 333B | |
+9.05% | 302B | |
+16.30% | 246B | |
+2.41% | 225B | |
+12.47% | 218B | |
+8.91% | 168B |
- Stock Market
- Equities
- PHRM Stock
- Financials PharmaTher Holdings Ltd.